BR0116255A - Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas e derivados de prostaglandina (1) - Google Patents

Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas e derivados de prostaglandina (1)

Info

Publication number
BR0116255A
BR0116255A BR0116255-1A BR0116255A BR0116255A BR 0116255 A BR0116255 A BR 0116255A BR 0116255 A BR0116255 A BR 0116255A BR 0116255 A BR0116255 A BR 0116255A
Authority
BR
Brazil
Prior art keywords
prostaglandins
pharmaceutical formulation
prostaglandin
calcium antagonists
thienopyrimidines
Prior art date
Application number
BR0116255-1A
Other languages
English (en)
Inventor
Hans-Michael Eggenweiler
Volker Eiermann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000163223 external-priority patent/DE10063223A1/de
Priority claimed from DE2000163885 external-priority patent/DE10063885A1/de
Priority claimed from DE2000164992 external-priority patent/DE10064992A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0116255A publication Critical patent/BR0116255A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"FORMULAçãO FARMACêUTICA COMPREENDENDO TIENOPIRIMIDINAS E ANTITROMBóTICOS, ANTAGONISTAS DE CáLCIO, PROSTAGLANDINAS E DERIVADOS DE PROSTAGLANDINA (1)". A presente invenção refere-se a uma preparação farmacêutica contendo pelo menos um composto da fórmula (1), em que R^ 1^, R^ 2^, R^ 3^, R^ 4^, n e X têm o significado como definido na reivindicação 1, e sais e/ou solvatos farmaceuticamente aceitáveis do mesmo e a) pelo menos um antitrombótico ou b) pelo menos um antagonista de cálcio ou c) pelo menos uma prostaglandina ou um derivado de prostaglandina para a preparação de um medicamento para o tratamento de angina, pressão sang³ínea elevada, hipertensão pulmonar, insuficiência cardíaca congestiva (CHF), doença pulmonar obstrutiva crónica (COPD), cor pulmonale, insuficiência dextrocardíaca, aterosclerose, condições de permeabilidade reduzida dos vasos cardíacos, doenças vasculares periféricas, acidente vascular cerebral, bronquite, asma alérgica, asma crónica, rinite alérgica, glaucoma, síndrome intestinal irritável, tumores, insuficiência renal, cirrose no fígado e para o tratamento de distúrbios sexuais feminino.
BR0116255-1A 2000-12-19 2001-11-28 Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas e derivados de prostaglandina (1) BR0116255A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2000163223 DE10063223A1 (de) 2000-12-19 2000-12-19 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Antithrombotica (1)
DE2000163885 DE10063885A1 (de) 2000-12-21 2000-12-21 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Calcium-Antagonisten (1)
DE2000164992 DE10064992A1 (de) 2000-12-23 2000-12-23 Pharmazeutische Formulierung enthaltend Thienopyrimidine und Prostaglandine oder Prostaglandinderivate (1)
PCT/EP2001/013915 WO2002049650A2 (de) 2000-12-19 2001-11-28 Pharmazeutische formulierung enthaltend thienopyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate

Publications (1)

Publication Number Publication Date
BR0116255A true BR0116255A (pt) 2003-12-30

Family

ID=27214207

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116255-1A BR0116255A (pt) 2000-12-19 2001-11-28 Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas e derivados de prostaglandina (1)

Country Status (16)

Country Link
US (1) US20040072846A1 (pt)
EP (1) EP1347761A2 (pt)
JP (1) JP2004516269A (pt)
KR (1) KR20030059351A (pt)
CN (1) CN1481242A (pt)
AR (1) AR032009A1 (pt)
AU (1) AU2002227957A1 (pt)
BR (1) BR0116255A (pt)
CA (1) CA2431074A1 (pt)
CZ (1) CZ20031754A3 (pt)
HU (1) HUP0303289A2 (pt)
MX (1) MXPA03005405A (pt)
NO (1) NO20032772D0 (pt)
PL (1) PL361805A1 (pt)
SK (1) SK8082003A3 (pt)
WO (1) WO2002049650A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20050107394A1 (en) * 2001-12-17 2005-05-19 Ardeschir Ghofrani Novel use of selective pde5 inhibitors
EP1628663B1 (en) * 2003-05-15 2009-07-29 Roskamp Research llc Method for producing medicaments for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
JP2006348024A (ja) * 2005-05-17 2006-12-28 Santen Pharmaceut Co Ltd アミジノ誘導体を有効成分として含む神経細胞の保護剤
US20090253765A1 (en) * 2005-05-17 2009-10-08 Santen Pharmaceutical Co., Ltd. Angiogenesis Inhibitor Containing Amine Derivative as Active Ingredient
US20090088472A1 (en) * 2005-05-17 2009-04-02 Kouji Oohashi Protective Agent for Neuronal Cell Comprising Amidino Derivative as Active Ingredient
NZ584729A (en) * 2007-10-05 2012-12-21 Alzheimer S Inst Of America Inc Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
MX2011006995A (es) * 2008-12-30 2011-09-27 Thrombologic Aps Metodos para identificar pacientes criticamente enfermos en riesgo incrementado de desarrollar nsuficiencia organica y compuestos para el tratamiento de la misma.
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
KR101643041B1 (ko) * 2014-04-25 2016-07-28 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2353285A1 (fr) * 1975-09-17 1977-12-30 Doms Laboratoires Medicament vasodilatateur coronarien perfectionne
JPS5459266A (en) * 1977-10-14 1979-05-12 Ono Pharmaceut Co Ltd Prostaglandin i2 analogs and their preparation
FR2568774B2 (fr) * 1984-05-30 1989-05-19 Choay Sa Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique
FR2672601B1 (fr) * 1991-02-08 1994-10-14 Synthelabo Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique.
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
JP2003525845A (ja) * 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
DE19752952A1 (de) * 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine

Also Published As

Publication number Publication date
CA2431074A1 (en) 2002-06-27
US20040072846A1 (en) 2004-04-15
WO2002049650A2 (de) 2002-06-27
SK8082003A3 (en) 2003-10-07
CZ20031754A3 (cs) 2003-09-17
PL361805A1 (en) 2004-10-04
MXPA03005405A (es) 2003-09-25
AU2002227957A1 (en) 2002-07-01
WO2002049650A3 (de) 2002-10-31
JP2004516269A (ja) 2004-06-03
CN1481242A (zh) 2004-03-10
EP1347761A2 (de) 2003-10-01
NO20032772L (no) 2003-06-18
NO20032772D0 (no) 2003-06-18
HUP0303289A2 (hu) 2004-01-28
KR20030059351A (ko) 2003-07-07
AR032009A1 (es) 2003-10-22

Similar Documents

Publication Publication Date Title
BR0115995A (pt) Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
BR0116255A (pt) Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas e derivados de prostaglandina (1)
EP2329825B1 (en) Method and composition for treating peripheral vascular diseases
BR0115247A (pt) Uso de tienopirimidinas
KR102196825B1 (ko) 녹내장 예방 또는 치료를 위한 약물 요법
BR0308166A (pt) Compostos de derivados de 8-azaprostaglandina e drogas contendo os compostos como o ingrediente ativo
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
EP0366279B1 (en) Ocular hypotensive agents
WO2002060423A3 (en) Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
JP2010510232A (ja) 眼圧降下剤であるプロスタグランジンプロドラッグ
BR0102252A (pt) Preparação de formulações de antogonistas dos receptores at1 usando as ciclodextrinas, seus derivados e os polìmeros biodegradáveis para o tratamento de hipertensão arterial, outras doenças cardiovasculares e suas complicações em animais de sangue quente
AU2007341218B2 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
BR9911274A (pt) Derivados da artemisinina, seus processos de preparação e as composições farmacêuticas que os contêm
BR0206853A (pt) Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina
RU2003122189A (ru) Сульфамидотиенопиримидины
BR0116247A (pt) Formulação farmacêutica compreendendo tienopirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina (2)
DK1458381T3 (da) Triazoler som oxytocinantagonister
BR0116849A (pt) Formulações farmacêuticas compreendendo pirazolo[4,3-d]pirimidinas e nitratos ou tienopirimidinas e nitratos
BR0115187A (pt) Uso de pirazolo[4,3-d]pirimidinas
KR19990028646A (ko) 안과용제
RU2003108860A (ru) Тиенопиримидины
KR20200012637A (ko) 에독사반을 포함하는 약학적 제제 및 이의 제조방법
CN104098647B (zh) 阿加曲班类似物及其制备方法和医药用途
KR20100029528A (ko) 아릴 디케토산（ａｄｋ） 유도체를 유효성분으로 포함하는 사스 코로나 바이러스 저해용 조성물

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]